

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Living experience of advanced cancer patients with low socioeconomic status: A protocol for systematic review of qualitative evidence

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-054606
Article Type:	Protocol
Date Submitted by the Author:	17-Jun-2021
Complete List of Authors:	An, Zifen; Wuhan University, Meng, Xianmei; Wuhan University Fang, Pei; Wuhan University School of Health Sciences, Yu, Huidan; Wuhan University Yu, Liping; Wuhan University
Keywords:	ONCOLOGY, QUALITATIVE RESEARCH, HEALTH ECONOMICS, Protocols & guidelines < HEALTH SERVICES ADMINISTRATION & MANAGEMENT

SCHOLARONE™
Manuscripts

1
2
3 Living experience of advanced cancer patients with low socioeconomic status: A
4 protocol for systematic review of qualitative evidence
5
6

7 Zifen An, Xianmei Meng, Pei Fang, Huidan Yu, Liping Yu
8
9

10 **All co-authors**

11
12 1. Zifen An, co-first author

13
14 Undergraduate, School of Health Sciences, Wuhan University. Located on No. 115
15 Donghu Road, Wuhan, Hubei province, 430071, China.
16

17
18 2. Xianmei Meng, co-first author

19
20 Assistant Professor, School of Health Sciences, Wuhan University. Located on No. 115
21 Donghu Road, Wuhan, Hubei province, 430071, China.
22

23
24 3. Pei Fang, the co-author

25
26 Master of Science, School of Health Sciences, Wuhan University. Located on No. 115
27 Donghu Road, Wuhan, Hubei province, 430071, China.
28
29

30 31 **Corresponding authors**

32
33 Huidan Yu, corresponding author

34
35 Assistant Professor, School of Health Sciences, Wuhan University. Located on No. 115
36 Donghu Road, Wuhan, Hubei province, 430071, China
37

38
39 E-mail: yuhuidan32@126.com
40
41

42
43 Liping Yu

44
45 Professor, School of Health Sciences, Wuhan University. Located on No. 115 Donghu
46 Road, Wuhan, Hubei province, 430071, China
47

48
49 E-mail: yuliping@whu.edu.cn
50
51

52
53 **Word count:** 1771 words
54
55
56
57
58
59
60

ABSTRACT

Introduction: The number of advanced cancer patients is rapidly increasing, and the disease burden among those with low socioeconomic status (SES) has accordingly become a global concern. Low SES can adversely impact patients with advanced cancer. The purpose of this systematic review is to identify the influencing factors of quality of life among advanced cancer patients with low SES to help provide targeted care strategies to improve their quality of life.

Methods and analysis: We will include the English databases Cochrane Library, Cumulative Index to Nursing and Allied Health Literature, PubMed, MEDLINE, Embase, Web of Science, Jonna Briggs Institute (JBI) Database of Systematic Reviews, PsycINFO, and OpenGrey and the Chinese databases China National Knowledge Infrastructure, VIP Database for Chinese Technical Periodicals, and Wanfang Data Knowledge Service Platform. A comprehensive search of qualitative studies on the experience of advanced cancer patients with low SES will be conducted from the above database, with no age limit setting in the search definition. Quality assessments of the studies will be independently performed by two reviewers using the JBI Critical Assessment Checklist, and any disagreements will be resolved through a discussion with a third reviewer. Relevant data will be extracted using JBI standardised data extraction tools. The JBI meta-aggregation tool will be used to compare, analyse, and summarise the original results. The reliability and credibility of the overall quality of the studies included will be evaluated using the JBI ConQual approach.

Ethics and dissemination: This study is based on existing public literature and therefore does not require a formal ethics review. If possible, the results of the study will be presented in peer-reviewed international journals and presented at scientific conferences.

PROSPERO registration number: CRD42021250423

Keywords: advanced cancer, socioeconomic status, systematic review

Strengths and limitations of this study

1. Many studies have reported the heavy economic burden imposed by advanced cancer to both patients and their families.
2. To our best knowledge, this study is the first qualitative review to focus on the living experience of advanced cancer patients with low SES; the findings may contribute to the improvement of relevant social welfare policies.
3. This study will include a systematic review of empirical evidence from qualitative research across multiple regions and cultures that will contribute to the dissemination of care practices for advanced cancer patients with low SES.
4. It is not possible to represent all advanced cancer patients with low SES in this review.

INTRODUCTION

Cancer remains the leading cause of death worldwide, and approximately 10 million cancer patients are projected to die by 2020.^[1] The global burden of cancer-related diseases is also increasing.^[2] Advanced cancer patients are defined as those with metastatic or controlled but incurable cancer.^[3] Although novel treatment modalities and quality of care strategies have improved the overall 5-year survival rate of patients with advanced cancer,^[4, 5] no curative cancer modality has been developed.^[6] Advanced cancer patients experience adverse health outcomes, and majority do not improve.^[7] Within the limited survival period of advanced cancer patients, the long-term consequences of cancer and its treatment often result in higher symptom loads,^[8, 9] including moderate to severe cancer pain,^[10] depression,^[11] malnutrition,^[12] and cancer-related fatigue.^[13] These in turn results in a significantly decreased quality of life,^[14] with severely impaired overall physical, psychological, and social functions and a higher risk of suicidal intentions.^[15]

Advanced cancer patients with low socioeconomic status (SES), that is, those with residence in a high-comprehensive development index (deprived) and with low income,^[16] face more complex problems.^[17] These patients often experience delays in perceiving nonspecific symptoms of certain cancers (e.g. fatigue or unexplained weight loss) until the time of diagnosis.^[18, 19] Further, active clinical treatment is often associated with higher out-of-pocket costs in these patients than their high SES counterparts.^[20-22] A systematic review by Irigorri et al.^[21] showed that cancer patients in low-income areas spent 42% of their annual income on cancer-related out-of-pocket expenses. This was approximately 2.6 times higher than the out-of-pocket expense-to-annual income ratio for cancer patients in high-income areas. Moreover, the debilitating effects of late illness often lead to unemployment for both patients and their caregivers,^[23, 24] further lowering the total household income. In addition, the economic cost of advanced cancer treatment is only partially covered by the social security system.^[22]

The negative impact of long-term and costly treatment and low income on the patients' quality of life is often multidimensional.^[25] Some studies have shown higher

1
2
3
4 drug non-compliance to save costs (e.g. reducing drug use, delaying prescriptions,
5 using alternative therapies) in advanced cancer patients with low SES.^[26, 27] Further,
6 these patients are forced to interrupt or abandon treatment.^[28, 29] Lower treatment
7 compliance can have more serious negative health-related consequences, including
8 increased hospitalisations ^[30] and higher mortality rates.^[17] A large National Health
9 Survey found that patients who reported “many” financial problems because of cancer
10 care costs were not only more likely to report lower health conditions, but also worse
11 mental health status.^[31] More severe symptoms of anxiety and depression lead to poorer
12 quality of life,^[32, 33] and this in turn increases the need for palliative care.^[34]

21 Despite these adverse effects of low SES, the care plan for advanced cancer
22 patients with low SES has not been clearly defined. Only a few quantitative studies
23 have explored meaningful nursing strategies for advanced cancer patients, including
24 symptom management ^[35] and psychosocial care.^[36, 37] However, these methods often
25 do not meet the daily care needs of advanced cancer patients with low SES.^[38] For
26 example, symptom management is continuous and dynamic, and more regular
27 medication use is better for symptom control. However, advanced patients with low
28 SES often adjust or delay medication due to their limited financial resources.^[26, 27, 39]
29 These patients also often lack access to adequate and continuous psychosocial care
30 services because of socioeconomic restrictions.^[40] Some qualitative studies have found
31 more life difficulties in advanced cancer patients with low SES. van Roij et al reported
32 that these patients feel overwhelmed but are also embarrassed when seeking financial
33 support.^[25] They also often experience stronger feelings of social exclusion and
34 isolation than their high SES counterparts.^[25] In addition, their strategies for accepting
35 and managing behavioural changes under such economic hardship may be unique.^[41]
36 For instance, the primary driver of pain control is their sensory experience of pain and
37 their perception of the meaning associated with pain, whereas the common intervention
38 method, which provides knowledge of pain management, is not instantaneous.^[42] These
39 patients also have their own nursing experience to manage with their difficulties.^[39]

57 Therefore, this qualitative review is aimed to gain a deeper understanding of the
58 life challenges and social adaption experience of advanced cancer patients with low
59
60

1
2
3
4 SES and to identify factors that influence their life experience to, ultimately, help
5 provide targeted care strategies to improve patients' health.
6
7
8

9 **METHODS AND ANALYSIS**

11 **Inclusion criteria**

13 **Studies**

14 We will review all studies on advanced cancer patients with low SES, without
15 limitations on country or type of cancer.
16
17

19 **Phenomenon of interest**

20 This review will include studies that describe the experiences of advanced cancer
21 patients with low SES.
22
23

25 **Context**

26 The context will consider the living experience of advanced cancer with low SES.
27
28

29 **Types of studies**

30 The review will consider qualitative studies, including, but not limited to, personal
31 narratives, grounded theories, ethnographies, and feminist research. Only English and
32 Chinese literature are included, and there are no restrictions on the year of
33 publication.
34
35
36
37

38 **Patient and public involvement**

39 No patient will be involved in the design, planning, and conception of this study.
40
41

42 **Search strategy**

43 The search strategy aims to find both published and grey literature. An initial search
44 will start with the PubMed and Cumulative Index to Nursing and Allied Health
45 Literature (CINAHL) databases. This will be followed by an analysis of MeSH
46 terminologies included in the title and abstract and index terminology terms used to
47 describe the articles. A comprehensive search will also be performed in the following
48 databases using relevant MeSH terminology and index terminology terms: the
49 Cochrane Library, CINAHL, PubMed, MEDLINE, Embase, Web of Science, Jonna
50 Briggs Institute (JBI) Database of Systematic Reviews, PsycINFO, China National
51 Knowledge Infrastructure, VIP Database for Chinese Technical Periodicals, Wanfang
52
53
54
55
56
57
58
59
60

Data Knowledge Service Platform, and OpenGrey. The complete search strategy for the customizations used in PubMed is presented in Appendix 1.

Study selection

All the identified studies will be collated and uploaded to EndNote X9 software; duplicate studies will be eliminated. Two independent reviewers (ZA and XM) will screen the titles and abstracts according to the inclusion criteria. Articles that do not meet the inclusion criteria will be excluded, and the reason for exclusion will be attached as an appendix in the final systematic review report. To maintain the credibility of the screening process, all included studies will be screened according to a rigorous process, and any disagreements will be resolved through discussion with a third reviewer.

Assessment of methodological quality

Quality assessments prior to inclusion in the review will be performed by two independent reviewers (ZA and XM) according to the 10-item checklist of the JBI Qualitative Assessment and Review Instrument for methodological validity.^[43] The checklist assesses different domains, including research methodology, philosophical foundation, data collection, analysis method, and result validity (**Table1**). All items are evaluated by 'yes', 'no', and 'unclear'. The result of the evaluation is determined by the number of eligible items in the 10 items, with a rating of ≤ 6 considered weak, 7-8 considered moderate, and 9-10 considered high quality. Any disagreements will be resolved through a discussion with a third reviewer (YH) until a consensus is reached. After establishing that all included studies have moderate to high quality, data will be extracted and integrated for analysis.

Table1. JBI Critical Assessment Checklist

Methodology	Yes	No	Unclear	Not applicable
1. Is there congruity between the stated philosophical perspective and the research methodology?				
2. Is there congruity between the research methodology and the research question or objectives?				

3. Is there congruity between the research methodology and the methods used to collect data?
4. Is there congruity between the research methodology and the representation and analysis of data?
5. Is there congruity between the research methodology and the interpretation of results?
6. Is there a statement locating the researcher culturally or theoretically?
7. Is the influence of the researcher on the research, and vice-versa, addressed?
8. Are participant, and their voices, adequately represented?
9. Is the research ethical according to current criteria or, for recent studies, and is there evidence of ethical approval by an appropriate body?
10. Do the conclusions drawn in the research report flow from the analysis or interpretation, of the data?

Overall appraisal: Include Exclude Seek further info

Comments (Including reason for exclusion):

Data collection

Two independent reviewers (ZA and XM) will collect qualitative data related to the research questions and objectives using the JBI qualitative assessment and review instrument from JBI SUMARI.^[44] The extracted data will include specific details about the populations, contexts, methods, culture, geographical location, study methods, and the phenomena of interest (**Table2**). All information obtained will be grouped into tables.

Table2. JBI Qualitative Assessment and Review Instrument Data Extraction

Study (Name and authors)	Methodology	Methods	Phenomenon of interest	Setting	Geographical location	Cultural	Participants	Data analysis	Author conclusion	Comments

Data synthesis

The collected data will be organised and synthesised using the JBI meta-aggregation method.^[45] Before integration, two independent reviewers (ZA and XM) will read the articles to initially understand the full text. They will then summarise the quality of the results and divide them into three levels: unequivocal, equivocal, and unsupported. These results will then be further classified to arrive at a set of concepts that are meaningful and consistent with the meaning of the original text. These similar categories are eventually integrated to produce a comprehensive set of findings that can improve the living experience of advanced cancer patients with low SES.

Assessing the accuracy of results

Ultimately, the accuracy of the final findings will be evaluated based on the JBI ConQual approach,^[46] which evaluates the reliability and credibility of the findings. The confidence level of the final study results will be classified into four scales of high, moderate, low, or very low (**Table3**). The process will be completed by two independent reviewers (ZA and XM), and any disagreement will be resolved through a discussion. The entire protocol is illustrated in [Figure1.pdf](#).

Table3. JBI ConQual summary of findings

Systematic review title: Living experience of advanced cancer patients with low socioeconomic status: A protocol for systematic review of qualitative evidence				
Population: Advanced cancer patients from low socioeconomic groups.				
Phenomena of interest: The living experience of advanced cancer patients with low socioeconomic status.				
Context: The experience and feelings of advanced cancer patients with low socioeconomic status.				
Synthesised finding	Type of research	Dependability	Credibility	ConQual score

Reporting of protocol

The findings of the comprehensive review of this qualitative study will be reported in accordance with the Enhancing Transparency in Reporting the Synthesis of Qualitative Research ^[47] to ensure rigidity of the review and research (**Table4**).

Table4. Enhancing transparency in reporting the synthesis of qualitative research: the ENTREQ statement

No	Item	Guide and description
1	Aim	State the research question the synthesis addresses.
2	Synthesis methodology	Identify the synthesis methodology or theoretical framework which underpins the synthesis and describe the rationale for choice of methodology.
3	Approach to searching	Indicate whether the search was pre-planned or iterative.
4	Inclusion criteria	Specify the inclusion/exclusion criteria.
5	Data sources	Describe the information sources used and when the searches conducted; provide the rationale for using the data sources.
6	Electronic Search strategy	Describe the literature search.
7	Study screening methods	Describe the process of study screening and sifting.
8	Study characteristics	Present the characteristics of the included studies.
9	Study selection results	Identify the number of studies screened and provide reasons for study exclusion.
10	Rationale for appraisal	Describe the rationale and approach used to appraise the included studies or selected findings.
11	Appraisal items	State the tools, frameworks, and criteria used to appraise the studies or selected findings.
12	Appraisal process	Indicate whether the appraisal was conducted independently by more than one reviewer and if consensus was required.
13	Appraisal results	Present results of the quality assessment and indicate which articles, if any, were weighted/excluded based on the assessment and give the rationale.
14	Data extraction	Indicate which sections of the primary studies were analysed and how were the data extracted from the primary studies?
15	Software	State the computer software used, if any.
16	Number of reviewers	Identify who was involved in coding and analysis.
17	Coding	Describe the process for coding of data.
18	Study comparison	Describe how were comparisons made within and across studies.
19	Derivation of themes	Explain whether the process of deriving the themes or constructs was inductive or deductive.

1		
2		
3		
4		
5		
6		
7		
8		
9		
10		
11		
12		
13		
14		
15		
16		
17		
18		
19		
20		
21		
22		
23		
24		
25		
26		
27		
28		
29		
30		
31		
32		
33		
34		
35		
36		
37		
38		
39		
40		
41		
42		
43		
44		
45		
46		
47		
48		
49		
50		
51		
52		
53		
54		
55		
56		
57		
58		
59		
60		
20	Quotations	Provide quotations from the primary studies to illustrate themes/constructs and identify whether the quotations were participant quotations of the author's interpretation.
21	Synthesis output	Present rich, compelling, and useful results that go beyond a summary of the primary studies.

ETHICS AND DISSEMINATION

This systematic review will identify and integrate the life experiences of advanced cancer patients with low SES to understand the other issues and needs of such vulnerable population, aside from financial barriers, to provide more targeted care that helps improve quality of life until death. The findings will be published in a peer-reviewed journal or presented at scientific conferences.

References

- 1 Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2021;71:209–49. doi:[10.3322/caac.21660](https://doi.org/10.3322/caac.21660).
- 2 Sullivan R, Peppercorn J, Sikora K, et al. Delivering affordable cancer care in high-income countries. *Lancet Oncol* 2011;12:933–80. doi:[10.1016/S1470-2045\(11\)70141-3](https://doi.org/10.1016/S1470-2045(11)70141-3).
- 3 Cancer AJCO. *American Cancer Society. What is advanced cancer?*, (Updated 2020-09-10); cited Date Accessed. <https://www.cancer.org> 2020.
- 4 Allemani C, Weir HK, Carreira H, et al. Global surveillance of cancer survival 1995–2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). *Lancet* 2015;385:977–1010. doi:[10.1016/S0140-6736\(14\)62038-9](https://doi.org/10.1016/S0140-6736(14)62038-9).
- 5 Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. *Lancet* 2018;391:1023–75. doi:[10.1016/S0140-6736\(17\)33326-3](https://doi.org/10.1016/S0140-6736(17)33326-3).
- 6 Wang JJ, Lei KF, Han F. Tumor microenvironment: recent advances in various cancer treatments. *Eur Rev Med Pharmacol Sci* 2018;22:3855–64. doi:[10.26355/eurrev_201806_15270](https://doi.org/10.26355/eurrev_201806_15270).
- 7 Foreman KJ, Marquez N, Dolgert A, et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016–40 for 195 countries and territories. *Lancet* 2018;392:2052–90. doi:[10.1016/S0140-6736\(18\)31694-5](https://doi.org/10.1016/S0140-6736(18)31694-5).
- 8 Kuon J, Vogt J, Mehnert A, et al. Symptoms and needs of patients with advanced lung cancer: early prevalence assessment. *Oncol Res Treat* 2019;42:650–9. doi:[10.1159/000502751](https://doi.org/10.1159/000502751).
- 9 Seow H, Barbera L, Sutradhar R, et al. Trajectory of performance status and symptom scores for patients with cancer during the last six months of life. *J Clin Oncol*

2011;29:1151–8. doi:[10.1200/JCO.2010.30.7173](https://doi.org/10.1200/JCO.2010.30.7173).

10 van den Beuken-van Everdingen MH, Hochstenbach LM, Joosten EA, et al. Update on Prevalence of Pain in Patients With Cancer: Systematic Review and Meta-Analysis. *J Pain Symptom Manage* 2016;51:1070-90.e9. doi:[10.1016/j.jpainsymman.2015.12.340](https://doi.org/10.1016/j.jpainsymman.2015.12.340).

11 Okuyama T, Akechi T, Mackenzie L, et al. Psychotherapy for depression among advanced, incurable cancer patients: A systematic review and meta-analysis. *Cancer Treat Rev* 2017;56:16–27. doi:[10.1016/j.ctrv.2017.03.012](https://doi.org/10.1016/j.ctrv.2017.03.012).

12 Ravasco P, Monteiro-Grillo I, Vidal PM, et al. Nutritional deterioration in cancer: the role of disease and diet. *Clin Oncol (R Coll Radiol)* 2003;15:443–50. doi:[10.1016/s0936-6555\(03\)00155-9](https://doi.org/10.1016/s0936-6555(03)00155-9).

13 Mohandas H, Jaganathan SK, Mani MP, et al. Cancer-related fatigue treatment: an overview. *J Cancer Res Ther* 2017;13:916–29. doi:[10.4103/jcrt.JCRT_50_17](https://doi.org/10.4103/jcrt.JCRT_50_17).

14 Ahlam A, Hind M, Haddou Rahou B, et al. Quality of life of Moroccan patients on the palliative phase of advanced cancer. *BMC Res Notes* 2019;12:351. doi:[10.1186/s13104-019-4390-1](https://doi.org/10.1186/s13104-019-4390-1).

15 McFarland DC, Walsh L, Napolitano S, et al. Suicide in patients with cancer: identifying the risk factors. *Oncology (Williston Park)* 2019;33:221–6.

16 Jang BS, Chang JH. Socioeconomic status and survival outcomes in elderly cancer patients: A national health insurance service-elderly sample cohort study. *Cancer Med* 2019;8:3604–13. doi:[10.1002/cam4.2231](https://doi.org/10.1002/cam4.2231).

17 Wang N, Cao F, Liu F, et al. The effect of socioeconomic status on health-care delay and treatment of esophageal cancer. *J Transl Med* 2015;13:241. doi:[10.1186/s12967-015-0579-9](https://doi.org/10.1186/s12967-015-0579-9).

18 Marcu A, Black G, Vedsted P, et al. Educational differences in responses to breast cancer symptoms: A qualitative comparative study. *Br J Health Psychol* 2017;22:26–41. doi:[10.1111/bjhp.12215](https://doi.org/10.1111/bjhp.12215).

19 McCutchan GM, Wood F, Edwards A, et al. Influences of cancer symptom knowledge, beliefs and barriers on cancer symptom presentation in relation to socioeconomic deprivation: a systematic review. *BMC Cancer* 2015;15:1000.

1
2
3
4 doi:[10.1186/s12885-015-1972-8](https://doi.org/10.1186/s12885-015-1972-8).

5
6 20 Zafar SY. Financial toxicity of cancer care: it's time to intervene. *J Natl Cancer*
7 *Inst* 2016;108. doi:[10.1093/jnci/djv370](https://doi.org/10.1093/jnci/djv370).

8
9
10 21 Irigorri N, de Oliveira C, Fitzgerald N, et al. The out-of-pocket cost burden of
11 cancer care-A systematic literature review. *Curr Oncol* 2021;28:1216–48.
12 doi:[10.3390/curroncol28020117](https://doi.org/10.3390/curroncol28020117).

13
14
15 22 Kankeu HT, Saksena P, Xu K, et al. The financial burden from non-communicable
16 diseases in low- and middle-income countries: a literature review. *Health Res Policy*
17 *Syst* 2013;11:31. doi:[10.1186/1478-4505-11-31](https://doi.org/10.1186/1478-4505-11-31).

18
19
20 23 Mols F, Tomalin B, Pearce A, et al. Financial toxicity and employment status in
21 cancer survivors. A systematic literature review. *Support Care Cancer* 2020;28:5693–
22 708. doi:[10.1007/s00520-020-05719-z](https://doi.org/10.1007/s00520-020-05719-z).

23
24
25 24 Azzani M, Roslani AC, Su TT. The perceived cancer-related financial hardship
26 among patients and their families: a systematic review. *Support Care Cancer*
27 2015;23:889–98. doi:[10.1007/s00520-014-2474-y](https://doi.org/10.1007/s00520-014-2474-y).

28
29
30 25 van Roij J, Brom L, Youssef-El Soud M, et al. Social consequences of advanced
31 cancer in patients and their informal caregivers: a qualitative study. *Support Care*
32 *Cancer* 2019;27:1187–95. doi:[10.1007/s00520-018-4437-1](https://doi.org/10.1007/s00520-018-4437-1).

33
34
35 26 Kaul S, Avila JC, Mehta HB, et al. Cost-related medication nonadherence among
36 adolescent and young adult cancer survivors. *Cancer* 2017;123:2726–34.
37 doi:[10.1002/cncr.30648](https://doi.org/10.1002/cncr.30648).

38
39
40 27 Chung GC, Marottoli RA, Cooney LM, et al. Cost-related medication
41 nonadherence among older adults: findings from a nationally representative sample. *J*
42 *Am Geriatr Soc* 2019;67:2463–73. doi:[10.1111/jgs.16141](https://doi.org/10.1111/jgs.16141).

43
44
45 28 Jan S, Laba TL, Essue BM, et al. Action to address the household economic burden
46 of non-communicable diseases. *Lancet* 2018;391:2047–58. doi:[10.1016/S0140-6736\(18\)30323-4](https://doi.org/10.1016/S0140-6736(18)30323-4).

47
48
49 29 Lim JN, Potrata B, Simonella L, et al. Barriers to early presentation of self-
50 discovered breast cancer in Singapore and Malaysia: a qualitative multicentre study.
51 *BMJ Open* 2015;5:e009863. doi:[10.1136/bmjopen-2015-009863](https://doi.org/10.1136/bmjopen-2015-009863).

- 1
2
3
4 30 Ruddy K, Mayer E, Partridge A. Patient adherence and persistence with oral
5 anticancer treatment. *CA Cancer J Clin* 2009;59:56–66. doi:[10.3322/caac.20004](https://doi.org/10.3322/caac.20004).
6
7
8 31 Fenn KM, Evans SB, McCorkle R, et al. Impact of financial burden of cancer on
9 survivors' quality of life. *J Oncol Pract* 2014;10:332–8.
10 doi:[10.1200/JOP.2013.001322](https://doi.org/10.1200/JOP.2013.001322).
11
12
13 32 Mongelli MN, Giri S, Peipert BJ, et al. Financial burden and quality of life among
14 thyroid cancer survivors. *Surgery* 2020;167:631–7. doi:[10.1016/j.surg.2019.11.014](https://doi.org/10.1016/j.surg.2019.11.014).
15
16
17 33 Jacob J, Palat G, Verghese N, et al. Health-related quality of life and its socio-
18 economic and cultural predictors among advanced cancer patients: evidence from the
19 APPROACH cross-sectional survey in Hyderabad-India. *BMC Palliat Care*
20 2019;18:94. doi:[10.1186/s12904-019-0465-y](https://doi.org/10.1186/s12904-019-0465-y).
21
22
23 34 Altice CK, Banegas MP, Tucker-Seeley RD, et al. Financial hardships experienced
24 by cancer survivors: A systematic review. *J Natl Cancer Inst* 2017;109.
25 doi:[10.1093/jnci/djw205](https://doi.org/10.1093/jnci/djw205).
26
27
28 35 van Dongen SI, de Nooijer K, Cramm JM, et al. Self-management of patients with
29 advanced cancer: A systematic review of experiences and attitudes. *Palliat Med*
30 2020;34:160–78. doi:[10.1177/0269216319883976](https://doi.org/10.1177/0269216319883976).
31
32
33 36 Cheng Q, Liu X, Li X, et al. Improving spiritual well-being among cancer patients:
34 implications for clinical care. *Support Care Cancer* 2019;27:3403–9.
35 doi:[10.1007/s00520-019-4636-4](https://doi.org/10.1007/s00520-019-4636-4).
36
37
38 37 Wang CW, Chow AY, Chan CL. The effects of life review interventions on
39 spiritual well-being, psychological distress, and quality of life in patients with terminal
40 or advanced cancer: A systematic review and meta-analysis of randomized controlled
41 trials. *Palliat Med* 2017;31:883–94. doi:[10.1177/0269216317705101](https://doi.org/10.1177/0269216317705101).
42
43
44 38 Lyckholm LJ, Coyne PJ, Kreutzer KO, et al. Barriers to effective palliative care for
45 low-income patients in late stages of cancer: report of a study and strategies for defining
46 and conquering the barriers. *Nurs Clin North Am* 2010;45:399–409.
47 doi:[10.1016/j.cnur.2010.03.007](https://doi.org/10.1016/j.cnur.2010.03.007).
48
49
50 39 Yeager KA, Sterk CE, Quest TE, et al. Managing One's symptoms: A qualitative
51 study of low-income African Americans with advanced cancer. *Cancer Nurs*
52
53
54
55
56
57
58
59
60

2016;39:303–12. doi:[10.1097/NCC.0000000000000284](https://doi.org/10.1097/NCC.0000000000000284).

40 Balboni T, Balboni M, Paulk ME, et al. Support of cancer patients' spiritual needs and associations with medical care costs at the end of life. *Cancer* 2011;117:5383–91. doi:[10.1002/cncr.26221](https://doi.org/10.1002/cncr.26221).

41 Fitch MI, Sharp L, Hanly P, et al. Experiencing financial toxicity associated with cancer in publicly funded healthcare systems: a systematic review of qualitative studies. *J Cancer Surviv* 2021. doi:[10.1007/s11764-021-01025-7](https://doi.org/10.1007/s11764-021-01025-7).

42 Hackett J, Godfrey M, Bennett MI. Patient and caregiver perspectives on managing pain in advanced cancer: A qualitative longitudinal study. *Palliat Med* 2016;30:711–9. doi:[10.1177/0269216316628407](https://doi.org/10.1177/0269216316628407).

43 Lockwood C, Munn Z, Porritt K. Qualitative research synthesis: methodological guidance for systematic reviewers utilizing meta-aggregation. *Int J Evid Based Healthc* 2015;13:179–87. doi:[10.1097/XEB.0000000000000062](https://doi.org/10.1097/XEB.0000000000000062).

44 Aromataris E, Briggs MZJ. *Institute reviewer's manual*. The Joanna Briggs Institute 2017.

45 Pearson A. Balancing the evidence: incorporating the synthesis of qualitative data into systematic reviews. *JBIC Rep* 2004;2:45–64. doi:[10.1111/j.1479-6988.2004.00008.x](https://doi.org/10.1111/j.1479-6988.2004.00008.x).

46 Munn Z, Porritt K, Lockwood C, et al. Establishing confidence in the output of qualitative research synthesis: the ConQual approach. *BMC Med Res Methodol* 2014;14:108. doi:[10.1186/1471-2288-14-108](https://doi.org/10.1186/1471-2288-14-108).

47 Tong A, Flemming K, McInnes E, et al. Enhancing transparency in reporting the synthesis of qualitative research: ENTREQ. *BMC Med Res Methodol* 2012;12:181. doi:[10.1186/1471-2288-12-181](https://doi.org/10.1186/1471-2288-12-181).

1
2
3
4 **Authors' contributions:** ZA and XM contributed to the conception and design of the
5 study. ZA and XM contributed equally. The introduction was finished by ZA and XM.
6
7 The methods, including literature retrieval, data extraction and appraisal, risk offset
8 assessment, and data synthesis, were drafted by HY and LY. In addition, PF, LY, and
9
10 HY assisted in clarifying differences to avoid errors. All authors contributed to the final
11 manuscript and agreed to its publication.
12
13

14
15 Funding: This work was supported by the Health Commission of Hubei Province
16 Scientific Research Project [grant number J2019M176].
17

18
19 Competing interests None declared.
20

21 Word count: 1771 words
22

23 Patient consent for publication Not required.
24

25 ORCID

26
27 Zifen An <https://orcid.org/0000-0002-1624-8153>
28

29 Xianmei Meng <https://orcid.org/0000-0003-0036-2733>
30

31 Pei Fang <https://orcid.org/0000-0003-1922-4955>
32

33 Huidan Yu <https://orcid.org/0000-0002-5353-3025>
34

35 Liping Yu <https://orcid.org/0000-0002-3202-3472>
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure1 PRISMA-P flow diagram of the protocol process. PRISMA-P, Preferred reporting items for systematic review and meta-analysis protocols.

Appendix 1: Search strategy

Example search strategy for PubMed

#1 "Neoplasms"[Mesh] OR "tumor"[Title/Abstract] OR "cancer" [Title/Abstract]
OR "carcinoma"[Title/Abstract]

#2 "terminal"[Title/Abstract] OR "advanced"[Title/Abstract] OR "late
stage"[Title/Abstract] OR "end stage"[Title/Abstract] OR "end of life"[Title/Abstract]
OR "metastatic"[Title/Abstract]

#3 "Social Class"[Mesh] OR "socioeconomic status"[Title/Abstract] OR
"socioeconomic"[Title/Abstract] OR "social environment"[Title/Abstract] OR "social
support"[Title/Abstract] OR "economic"[Title/Abstract] OR "poor"[Title/Abstract]
OR "income"[Title/Abstract] OR "low income"[Title/Abstract] OR
"poverty"[Title/Abstract] OR "unemployment"[Title/Abstract] OR
"employment"[Title/Abstract]

#4 "Qualitative Research"[Mesh] OR "Focus Groups"[Mesh] OR "Interview as
topic"[Mesh] OR "Hermeneutics"[Mesh] OR "Grounded Theory"[Mesh] OR
"Personal Narrative"[Mesh] OR "Feminism"[Mesh] OR "Life Change Events"[Mesh]
OR "Anthropology, Cultural"[Mesh] OR "qualitative"[Title/Abstract] OR "group
focus"[Title/Abstract] OR "groups focus"[Title/Abstract] OR "grounded
theory"[Title/Abstract] OR "grounded analysis"[Title/Abstract] OR "grounded
analyses"[Title/Abstract] OR (stud*[Title/Abstract] AND "grounded"[Title/Abstract])
OR "narrative analysis"[Title/Abstract] OR "feminist ethics"[Title/Abstract] OR
"ethics, feminist "[Title/Abstract] OR (experience*[Title/Abstract] AND
"life"[Title/Abstract]) OR "analysis, event history"[Title/Abstract] OR "event history
analysis"[Title/Abstract] OR experience*[Title/Abstract] OR "Cultural
Anthropology"[Title/Abstract] OR ethnograph*[Title/Abstract]

#5 #1 AND #2 AND #3 AND #4

Reporting checklist for protocol of a systematic review and meta-analysis.

Based on the PRISMA-P guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the PRISMA-Reporting guidelines, and cite them as:

Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1.

			Page
		Reporting Item	Number
Title			
Identification	#1a	Identify the report as a protocol of a systematic review	1
Update	#1b	If the protocol is for an update of a previous systematic review, identify as such	n/a

Registration

[#2](#) If registered, provide the name of the registry (such as PROSPERO) and registration number 2

Authors

[#3a](#) Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author 1

[#3b](#) Describe contributions of protocol authors and identify the guarantor of the review 17

Amendments

[#4](#) If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments n/a

Support

[#5a](#) Indicate sources of financial or other support for the review 17

[#5b](#) Provide name for the review funder and / or sponsor 17

[#5c](#) Describe roles of funder(s), sponsor(s), and / or institution(s), if any, in developing the protocol 17

Introduction

[#6](#) Describe the rationale for the review in the context of what is 4,5,6

1		already known	
2			
3			
4	Objectives	#7 Provide an explicit statement of the question(s) the review will	6
5		address with reference to participants, interventions,	
6		comparators, and outcomes (PICO)	
7			
8			
9			
10			
11	Methods		
12			
13			
14	Eligibility criteria	#8 Specify the study characteristics (such as PICO, study design,	6,7
15		setting, time frame) and report characteristics (such as years	
16		considered, language, publication status) to be used as	
17		criteria for eligibility for the review	
18			
19			
20			
21			
22			
23			
24	Information	#9 Describe all intended information sources (such as electronic	6
25		databases, contact with study authors, trial registers or other	
26	sources	grey literature sources) with planned dates of coverage	
27			
28			
29			
30			
31			
32	Search strategy	#10 Present draft of search strategy to be used for at least one	7
33		electronic database, including planned limits, such that it	
34		could be repeated	
35			
36			
37			
38			
39	Study records -	#11a Describe the mechanism(s) that will be used to manage	7
40		records and data throughout the review	
41	data management		
42			
43			
44			
45	Study records -	#11b State the process that will be used for selecting studies (such	7
46		as two independent reviewers) through each phase of the	
47	selection process	review (that is, screening, eligibility and inclusion in meta-	
48		analysis)	
49			
50			
51			
52			
53			
54	Study records -	#11c Describe planned method of extracting data from reports	8,9
55		(such as piloting forms, done independently, in duplicate), any	
56	data collection		
57			
58			
59			
60			

1	process		processes for obtaining and confirming data from investigators	
2				
3				
4	Data items	#12	List and define all variables for which data will be sought	8,9
5			(such as PICO items, funding sources), any pre-planned data	
6			assumptions and simplifications	
7				
8				
9				
10				
11	Outcomes and	#13	List and define all outcomes for which data will be sought,	n/a
12				
13	prioritization		including prioritization of main and additional outcomes, with	
14			rationale	
15				
16				
17				
18				
19	Risk of bias in	#14	Describe anticipated methods for assessing risk of bias of	9
20				
21	individual studies		individual studies, including whether this will be done at the	
22			outcome or study level, or both; state how this information will	
23			be used in data synthesis	
24				
25				
26				
27				
28				
29	Data synthesis	#15a	Describe criteria under which study data will be quantitatively	n/a
30			synthesised	
31				
32				
33				
34	Data synthesis	#15b	If data are appropriate for quantitative synthesis, describe	n/a
35			planned summary measures, methods of handling data and	
36			methods of combining data from studies, including any	
37			planned exploration of consistency (such as I ² , Kendall's τ)	
38				
39				
40				
41				
42				
43				
44	Data synthesis	#15c	Describe any proposed additional analyses (such as	n/a
45			sensitivity or subgroup analyses, meta-regression)	
46				
47				
48				
49	Data synthesis	#15d	If quantitative synthesis is not appropriate, describe the type	9
50			of summary planned	
51				
52				
53				
54	Meta-bias(es)	#16	Specify any planned assessment of meta-bias(es) (such as	n/a
55			publication bias across studies, selective reporting within	
56				
57				
58				
59				
60				

studies)

Confidence in [#17](#) Describe how the strength of the body of evidence will be assessed (such as GRADE) 9,10,11
cumulative
evidence

Notes:

- 1b: n/a. This is a protocol for a new systematic review.
- 4: n/a. This protocol will be published for the first time.
- 15a, 15b, 15c,16: n/a. This is an integration of qualitative evidence, and the criteria for quantitative synthesis do not apply.

The PRISMA-P elaboration and explanation paper is distributed under the terms of the Creative Commons Attribution License CC-BY. This checklist was completed on 17. June 2021 using <https://www.goodreports.org/>, a tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)

BMJ Open

Living experiences of advanced cancer patients with low socioeconomic status: Protocol for a systematic review of qualitative evidence

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-054606.R1
Article Type:	Protocol
Date Submitted by the Author:	25-Nov-2021
Complete List of Authors:	An, Zifen; Wuhan University, School of Nursing Meng, Xianmei; Wuhan University, School of Nursing Fang, Pei; Wuhan University, School of Nursing Yu, Huidan; Wuhan University, School of Nursing Yu, Liping; Wuhan University, School of Nursing
Primary Subject Heading:	Oncology
Secondary Subject Heading:	Nursing, Oncology
Keywords:	ONCOLOGY, QUALITATIVE RESEARCH, HEALTH ECONOMICS, Protocols & guidelines < HEALTH SERVICES ADMINISTRATION & MANAGEMENT

SCHOLARONE™
Manuscripts

1 Living experiences of advanced cancer patients with low socioeconomic status: Protocol for a systematic
2 review of qualitative evidence

3
4 Zifen An, Xianmei Meng, Pei Fang, Huidan Yu, Liping Yu

5
6
7
8
9
10
11 **All co-authors**

12
13 1. Zifen An, co-first author

14 Master of Science, School of Nursing, Wuhan University. Located on No. 115 Donghu Road, Wuhan,
15 Hubei province, 430071, China.

16
17 2. Xianmei Meng, co-first author

18 Assistant Professor, School of Nursing, Wuhan University. Located on No. 115 Donghu Road, Wuhan,
19 Hubei province, 430071, China.

20
21 3. Pei Fang, the co-author

22 Master of Science, School of Nursing, Wuhan University. Located on No. 115 Donghu Road, Wuhan,
23 Hubei province, 430071, China.

24
25
26
27
28
29
30
31
32 **Corresponding authors**

33 Huidan Yu

34 Assistant Professor, School of Nursing, Wuhan University. Located on No. 115 Donghu Road, Wuhan,
35 Hubei province, 430071, China

36 E-mail: yuhuidan32@126.com

37
38
39
40
41
42
43
44 Liping Yu

45 Professor, School of Nursing, Wuhan University. Located on No. 115 Donghu Road, Wuhan, Hubei
46 province, 430071, China

47 E-mail: yuliping@whu.edu.cn

48
49
50
51
52
53 **Word count:** 1835 words

1
2
3 30 **ABSTRACT**
4

5 31 **Introduction:** The number of patients with advanced cancer is rapidly increasing, and the disease burden
6 32 among those with low socioeconomic status (SES) has accordingly become a global concern. Low SES
7 33 can adversely impact patients with advanced cancer. The purpose of this systematic review is to shed
8
9 34 light on the life experiences of advanced cancer patients with low SES to help provide targeted and
10
11
12
13 35 effective strategies to improve their quality of life.

14 36 **Methods and analysis:** We will include the following English databases: Cochrane Library, Cumulative
15
16 37 Index to Nursing and Allied Health Literature, PubMed, MEDLINE, Embase, Web of Science, Joanna
17
18 38 Briggs Institute (JBI) Database of Systematic Reviews, PsycINFO, and OpenGrey, and the following
19
20 39 Chinese databases: China National Knowledge Infrastructure, VIP Database for Chinese Technical
21
22 40 Periodicals, and Wanfang Data Knowledge Service Platform. A comprehensive search of qualitative
23
24 41 studies on the experiences of advanced cancer patients with low SES will be conducted from the above
25
26 42 databases, with no age limit. Quality assessments of the studies will be independently performed by two
27
28 43 reviewers using the JBI Critical Assessment Checklist, and any disagreements will be resolved through
29
30 44 a discussion with a third reviewer. Relevant data will be extracted using the JBI standardised data
31
32 45 extraction tools. The JBI meta-aggregation tool will be used to compare, analyse, and summarise the
33
34 46 original results. The reliability and credibility of the overall quality of the studies included will be
35
36 47 evaluated using the JBI ConQual approach.

37
38 48 **Ethics and dissemination:** This study is based on existing public literature and therefore does not require
39
40 49 a formal ethics review. The results of the study may be presented in peer-reviewed international journals
41
42 50 and presented at scientific conferences.

43
44 51 **PROSPERO registration number:** CRD42021250423
45

46 52
47 53 **Keywords:** advanced cancer, socioeconomic status, systematic review, qualitative study
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

54 **Strengths and limitations of this study**

- 55 1. There is an urgent need for qualitative evidence about regarding the life experiences of advanced
56 cancer patients with low socioeconomic status (SES) to help formulate appropriate interventions.
- 57 2. This study is the first qualitative systematic review to focus on the living experiences of advanced
58 cancer patients with low SES.
- 59 3. This study will include a systematic review of empirical evidence based on qualitative research
60 conducted across multiple regions and cultures that will contribute to the dissemination of care
61 practices for advanced cancer patients with low SES.
- 62 4. The findings of this qualitative systematic review are limited by the context and background of the
63 included original studies.

64 INTRODUCTION

65 Cancer remains the leading cause of death worldwide, and an estimated 10 million cancer death
66 occurred in 2020.^[1] The global burden of cancer-related diseases is also increasing.^[2] Patients with
67 advanced cancer are those with metastatic or controlled but incurable cancer.^[3] Although novel treatment
68 modalities and the quality of care strategies have improved the overall 5-year survival rate of patients
69 with advanced cancer,^[4, 5] no curative cancer modality has been developed.^[6] Patients with advanced
70 cancer experience adverse health outcomes, and majority do not recover.^[7] Within the limited survival
71 period of patients with advanced cancer, the long-term consequences of cancer and its treatment often
72 result in higher symptom loads,^[8, 9] including moderate to severe cancer pain,^[10] depression,^[11]
73 malnutrition,^[12] and cancer-related fatigue.^[13] These, in turn, result in a significantly decreased quality
74 of life,^[14] with severely impaired overall physical, psychological, and social functions and a higher risk
75 of suicidal intentions.^[15]

76 Advanced cancer patients with low socioeconomic status (SES), i.e. those generally either with
77 residence in a deprived regional status or with low income,^[16] face more complex problems.^[17] Despite
78 their varying types of cancer, advanced cancer patients with low SES have similar concerns and issues.
79 They often experience delays in perceiving nonspecific symptoms of certain cancers (e.g. fatigue or
80 unexplained weight loss) until the time of diagnosis.^[18, 19] Further, active clinical treatment is often
81 associated with higher out-of-pocket costs in these patients than their high-SES counterparts.^[20-22] A
82 systematic review by Iraragorri et al.^[21] showed that patients with cancer residing in low-income areas
83 spent 42% of their annual income on cancer-related out-of-pocket expenses. This was approximately 2.6
84 times higher than the out-of-pocket expense-to-annual income ratio for cancer patients in high-income
85 areas. Moreover, the debilitating effects of late illness often lead to unemployment for both patients and
86 their caregivers,^[23, 24] further lowering the total household income. In addition, the economic cost of
87 advanced cancer treatment is only partially covered by the social security system.^[22]

88 The negative impact of long-term and costly treatment and low income on the patients' quality of
89 life is often multidimensional.^[25] Some studies have shown patients' higher drug non-compliance to save
90 costs (e.g. reducing drug use, delaying prescriptions, using alternative therapies) in advanced cancer
91 patients with low SES.^[26, 27] Further, these patients are forced to interrupt or abandon treatment.^[28, 29]
92 Lower treatment compliance can have significantly negative health-related consequences, including
93 increased hospitalisations^[30] and higher mortality rates.^[17] A large National Health Survey found that

1
2
3
4 94 patients who reported having financial problems because of cancer care costs were not only more likely
5
6 95 to report lower health conditions, but also had worse mental health status.^[31] Severe symptoms of anxiety
7
8 96 and depression lead to poorer quality of life,^[32, 33] which increases the need for palliative care.^[34]
9

10 97 Despite these adverse effects of low SES, the care plan for advanced cancer patients with low SES
11
12 98 has not been clearly defined. Only a few quantitative studies have explored effective nursing strategies
13
14 99 for patients with advanced cancer, including symptom management ^[35] and psychosocial care.^[36, 37]
15
16 100 However, these methods often do not meet the daily care needs of advanced cancer patients with low
17
18 101 SES.^[38] For example, symptom management is continuous and dynamic, and regular medication use is
19
20 102 better for symptom control. However, advanced cancer patients with low SES often adjust or delay
21
22 103 medication due to their limited financial resources.^[26, 27, 39] These patients also often lack access to
23
24 104 adequate and continuous psychosocial care services because of socioeconomic restrictions.^[40] Some
25
26 105 qualitative studies have found more life difficulties in advanced cancer patients with low SES. van Roij
27
28 106 et al reported that patients in their study felt overwhelmed but were embarrassed when seeking financial
29
30 107 support.^[25] These patients also often experience stronger feelings of social exclusion and isolation than
31
32 108 their high SES counterparts.^[25] In addition, their strategies for accepting and managing behavioural
33
34 109 changes under such economic hardship may be unique.^[41] For instance, the more effective strategies of
35
36 110 pain management among these patients were found as the sensory experience of pain and the meaning
37
38 111 of pain, rather than prescribed analgesics.^[39]

39 112 Therefore, this qualitative review aims to shed light on of the life experiences of advanced cancer
40
41 113 patients with low SES, in a detailed manner, including disease distress, barriers, and strategies in coping
42
43 114 with the disease distress. Ultimately, the synthesised qualitative evidence helps provide targeted and
44
45 115 appropriate care strategies to improve patients' quality of life.
46

47 116

48 117 **METHODS AND ANALYSIS**

49 118 This is a qualitative systematic review protocol that follows the Preferred Reporting Items for
50
51 119 Systematic Reviews and Meta-analyses Protocols (PRISMA-P) checklist to ensure that the research
52
53 120 plan is robust (Supplemental material 1).

55 121 **Inclusion criteria**

57 122 **Participants**

1
2
3
4 123 We will review all studies that include patients with advanced cancer, without limitations on the
5
6 124 country or type of cancer.

7 125 **Phenomenon of interest**

9 126 This review will include studies that describe the life experiences of patients with advanced cancer,
10
11 127 including disease distress, barriers, and strategies in detail.

13 128 **Context**

15 129 The context will consider the life experiences of advanced cancer patients with low SES. According to
16
17 130 literature review, most previous studies identified low income as a feature of low SES. [16, 17, 19]
18
19 131 Therefore, low income will be considered as low SES in this study. Also, due to the varying standards
20
21 132 of low income in different locations, patients with advanced cancer who are identified as having a low-
22
23 133 income economic status in the original research will be included in this study.

25 134 **Types of studies**

27 135 The review will consider qualitative studies, including, but not limited to, personal narratives, grounded
28
29 136 theories, ethnographies, and feminist research. Only English and Chinese literature will be included,
30
31 137 and there will be no restrictions on the year of publication.

33 138 **Patient and public involvement**

35 139 No patient will be involved in the design, planning, and conception of this study.

37 140 **Search strategy**

39 141 The search strategy aims to find both published and grey literature. An initial search will be conducted
40
41 142 using the PubMed and Cumulative Index to Nursing and Allied Health Literature (CINAHL) databases.
42
43 143 This will be followed by an analysis of MesH terminologies included in the title and abstract and index
44
45 144 terminology terms used to describe the articles. A comprehensive search will also be performed, using
46
47 145 the relevant MesH terminology and index terminology terms, in the following databases: the Cochrane
48
49 146 Library, CINAHL, PubMed, MEDLINE, Embase, Web of Science, Joanna Briggs Institute (JBI)
50
51 147 Database of Systematic Reviews, PsycINFO, China National Knowledge Infrastructure, VIP Database
52
53 148 for Chinese Technical Periodicals, Wanfang Data Knowledge Service Platform, and OpenGrey. The
54
55 149 complete search strategy for the customizations used in PubMed is presented in Supplemental material
56
57 150 2.

58 151 **Study selection**

1
2
3
4 152 All the identified studies will be collated and uploaded to EndNote X9 software; duplicate studies will
5
6 153 be eliminated. Two independent reviewers (ZA and XM) will screen the titles and abstracts according
7
8 154 to the inclusion criteria. Articles that do not meet the inclusion criteria will be excluded, and the reason
9
10 155 for exclusion will be attached as supplemental material in the final systematic review report. To
11
12 156 maintain the credibility of the screening process, all included studies will be screened according to a
13
14 157 rigorous process, and any disagreements will be resolved through discussion with a third reviewer
15
16 158 (HY).

17 159 **Assessment of methodological quality**

18
19 160 Quality assessments prior to inclusion in the review will be performed by two independent reviewers
20
21 161 (ZA and XM) according to the 10-item checklist of the JBI Qualitative Assessment and Review
22
23 162 Instrument for methodological validity.^[42] The checklist assesses different domains, including research
24
25 163 methodology, philosophical foundation, data collection, analysis method, and result validity
26
27 164 (Supplemental material 3). All studies will be evaluated based on whether or not the study being
28
29 165 evaluated fulfills the checklist item for each domain. Items in the checklist will be marked as 'yes' if the
30
31 166 study fulfills the domain criteria, 'no' if it does not, and 'unclear' if the study's adherence to certain
32
33 167 domain criteria cannot be conclusively proven. The result of the evaluation will be determined based
34
35 168 on the number of domain items (of a total of 10) that the study fulfils, with a rating of ≤ 6 considered
36
37 169 weak, 7–8 considered moderate, and 9–10 considered high quality. Any disagreements will be resolved
38
39 170 through a discussion with the third reviewer (HY) until a consensus is reached. For studies that are
40
41 171 evaluated as moderate and above, data will be extracted and integrated for analysis.

42
43 172

44 173 **Data collection**

45
46 174 Two independent reviewers (ZA and XM) will collect qualitative data related to the research questions
47
48 175 and objectives using the JBI qualitative assessment and review instrument from the JBI System for the
49
50 176 Unified Management, Assessment and Review of Information.^[43] The extracted data will include details
51
52 177 regarding the populations, contexts, methods, culture, geographical location, study methods, and the
53
54 178 phenomena of interest (Supplemental material 4). All information obtained will be grouped into tables.

55
56 179

57 180 **Data synthesis**

1
2
3
4 181 The collected data will be organised and synthesised using the JBI meta-aggregation method.^[44] Before
5
6 182 integration, two independent reviewers (ZA and XM) will read the articles to understand the full text.
7
8 183 They will then summarise the quality of the results and divide them into three levels: unequivocal,
9
10 184 unequivocal, and unsupported. These results will then be further classified to arrive at a set of meaningful
11
12 185 concepts that are consistent with those of the original manuscript. These similar categories are eventually
13
14 186 integrated to produce a comprehensive set of findings that can improve the living experiences of
15
16 187 advanced cancer patients with low SES.
17
18 188

19 189 **Assessing the accuracy of results**

20
21 190 Ultimately, the accuracy of the findings will be evaluated based on the JBI ConQual approach,^[45] which
22
23 191 evaluates the reliability and credibility of the findings. The confidence level of the final study results will
24
25 192 be classified into four scales of high, moderate, low, or very low (Supplemental material 5). The process
26
27 193 will be completed by two independent reviewers (ZA and XM), and any disagreement will be resolved
28
29 194 through a discussion. The entire protocol process is illustrated in Figure: Figure 1.
30
31 195

32 196 **Reporting of protocol**

33
34 197 The findings of the comprehensive review in this qualitative study will be reported in accordance with
35
36 198 the Enhancing Transparency in Reporting the Synthesis of Qualitative Research^[46] guideline to ensure
37
38 199 that the review and research is robust (Supplemental material 6).
40
41 200

42 201 **ETHICS AND DISSEMINATION**

43
44 202 This systematic review will identify and integrate the life experiences of advanced cancer patients with
45
46 203 low SES to understand the other issues and needs of such a vulnerable population, apart from financial
47
48 204 barriers, to provide targeted care to improve patients' quality of life. The findings will be published in a
49
50 205 peer-reviewed journal or presented at scientific conferences.
51
52 206
53
54 207

References

- 1
2
3
4 208
- 5
6 209 1 Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of
7
8 210 incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2021;71:209–49.
9
10 211 doi:[10.3322/caac.21660](https://doi.org/10.3322/caac.21660).
- 11
12 212 2 Sullivan R, Peppercorn J, Sikora K, et al. Delivering affordable cancer care in high-income
13
14 213 countries. *Lancet Oncol* 2011;12:933–80. doi:[10.1016/S1470-2045\(11\)70141-3](https://doi.org/10.1016/S1470-2045(11)70141-3).
- 15
16 214 3 Cancer AJCO. *American Cancer Society. What is advanced cancer?*;2020. <https://www.cancer.org>
17
18 215 2020 updated 2020-09-10; cited Date Accessed.
- 19
20 216 4 Allemani C, Weir HK, Carreira H, et al. Global surveillance of cancer survival 1995–2009: analysis
21
22 217 of individual data for 25,676,887 patients from 279 population-based registries in 67 countries
23
24 218 (CONCORD-2). *Lancet* 2015;385:977–1010. doi:[10.1016/S0140-6736\(14\)62038-9](https://doi.org/10.1016/S0140-6736(14)62038-9).
- 25
26 219 5 Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000–14
27
28 220 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers
29
30 221 from 322 population-based registries in 71 countries. *Lancet* 2018;391:1023–75. doi:[10.1016/S0140-](https://doi.org/10.1016/S0140-6736(17)33326-3)
31
32 222 [6736\(17\)33326-3](https://doi.org/10.1016/S0140-6736(17)33326-3).
- 33
34 223 6 Wang JJ, Lei KF, Han F. Tumor microenvironment: recent advances in various cancer treatments.
35
36 224 *Eur Rev Med Pharmacol Sci* 2018;22:3855–64. doi:[10.26355/eurrev_201806_15270](https://doi.org/10.26355/eurrev_201806_15270).
- 37
38 225 7 Foreman KJ, Marquez N, Dolgert A, et al. Forecasting life expectancy, years of life lost, and all-
39
40 226 cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016–
41
42 227 40 for 195 countries and territories. *Lancet* 2018;392:2052–90. doi:[10.1016/S0140-6736\(18\)31694-5](https://doi.org/10.1016/S0140-6736(18)31694-5).
- 43
44 228 8 Kuon J, Vogt J, Mehnert A, et al. Symptoms and needs of patients with advanced lung cancer: early
45
46 229 prevalence assessment. *Oncol Res Treat* 2019;42:650–9. doi:[10.1159/000502751](https://doi.org/10.1159/000502751).
- 47
48 230 9 Seow H, Barbera L, Sutradhar R, et al. Trajectory of performance status and symptom scores for
49
50 231 patients with cancer during the last six months of life. *J Clin Oncol* 2011;29:1151–8.
51
52 232 doi:[10.1200/JCO.2010.30.7173](https://doi.org/10.1200/JCO.2010.30.7173).
- 53
54 233 10 van den Beuken-van Everdingen MH, Hochstenbach LM, Joosten EA, et al. Update on prevalence
55
56 234 of pain in patients with cancer: systematic review and meta-analysis. *J Pain Symptom Manage*
57
58 235 2016;51:1070–90.e9. doi:[10.1016/j.jpainsymman.2015.12.340](https://doi.org/10.1016/j.jpainsymman.2015.12.340).
- 59
60 236 11 Okuyama T, Akechi T, Mackenzie L, et al. Psychotherapy for depression among advanced,

- 1
2
3
4 237 incurable cancer patients: a systematic review and meta-analysis. *Cancer Treat Rev* 2017;56:16–27.
5
6 238 doi:[10.1016/j.ctrv.2017.03.012](https://doi.org/10.1016/j.ctrv.2017.03.012).
- 7
8 239 12 Ravasco P, Monteiro-Grillo I, Vidal PM, et al. Nutritional deterioration in cancer: the role of disease
9
10 240 and diet. *Clin Oncol (R Coll Radiol)* 2003;15:443–50. doi:[10.1016/s0936-6555\(03\)00155-9](https://doi.org/10.1016/s0936-6555(03)00155-9).
- 11
12 241 13 Mohandas H, Jaganathan SK, Mani MP, et al. Cancer-related fatigue treatment: an overview. *J*
13
14 242 *Cancer Res Ther* 2017;13:916–29. doi:[10.4103/jcrt.JCRT_50_17](https://doi.org/10.4103/jcrt.JCRT_50_17).
- 15
16 243 14 Ahlam A, Hind M, Haddou Rahou B, et al. Quality of life of Moroccan patients on the palliative
17
18 244 phase of advanced cancer. *BMC Res Notes* 2019;12:351. doi:[10.1186/s13104-019-4390-1](https://doi.org/10.1186/s13104-019-4390-1).
- 19
20 245 15 McFarland DC, Walsh L, Napolitano S, et al. Suicide in patients with cancer: identifying the risk
21
22 246 factors. *Oncology (Williston Park)* 2019;33:221–6.
- 23
24 247 16 Jang BS, Chang JH. Socioeconomic status and survival outcomes in elderly cancer patients: a
25
26 248 national health insurance service-elderly sample cohort study. *Cancer Med* 2019;8:3604–13.
27
28 249 doi:[10.1002/cam4.2231](https://doi.org/10.1002/cam4.2231).
- 29
30 250 17 Wang N, Cao F, Liu F, et al. The effect of socioeconomic status on health-care delay and treatment
31
32 251 of esophageal cancer. *J Transl Med* 2015;13:241. doi:[10.1186/s12967-015-0579-9](https://doi.org/10.1186/s12967-015-0579-9).
- 33
34 252 18 Marcu A, Black G, Vedsted P, et al. Educational differences in responses to breast cancer symptoms:
35
36 253 a qualitative comparative study. *Br J Health Psychol* 2017;22:26–41. doi:[10.1111/bjhp.12215](https://doi.org/10.1111/bjhp.12215).
- 37
38 254 19 McCutchan GM, Wood F, Edwards A, et al. Influences of cancer symptom knowledge, beliefs and
39
40 255 barriers on cancer symptom presentation in relation to socioeconomic deprivation: a systematic review.
41
42 256 *BMC Cancer* 2015;15:1000. doi:[10.1186/s12885-015-1972-8](https://doi.org/10.1186/s12885-015-1972-8).
- 43
44 257 20 Zafar SY. Financial toxicity of cancer care: it's time to intervene. *J Natl Cancer Inst* 2016;108.
45
46 258 doi:[10.1093/jnci/djv370](https://doi.org/10.1093/jnci/djv370).
- 47
48 259 21 Iragorri N, de Oliveira C, Fitzgerald N, et al. The out-of-pocket cost burden of cancer care-A
49
50 260 systematic literature review. *Curr Oncol* 2021;28:1216–48. doi:[10.3390/curroncol28020117](https://doi.org/10.3390/curroncol28020117).
- 51
52 261 22 Kankeu HT, Saksena P, Xu K, et al. The financial burden from non-communicable diseases in low-
53
54 262 and middle-income countries: a literature review. *Health Res Policy Syst* 2013;11:31. doi:[10.1186/1478-
55 263 4505-11-31](https://doi.org/10.1186/1478-4505-11-31).
- 56
57 264 23 Mols F, Tomalin B, Pearce A, et al. Financial toxicity and employment status in cancer survivors.
58
59 265 a systematic literature review. *Support Care Cancer* 2020;28:5693–708. doi:[10.1007/s00520-020-
60 266 05719-z](https://doi.org/10.1007/s00520-020-05719-z).

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 267 24 Azzani M, Roslani AC, Su TT. The perceived cancer-related financial hardship among patients and
268 their families: a systematic review. *Support Care Cancer* 2015;23:889–98. doi:[10.1007/s00520-014-](https://doi.org/10.1007/s00520-014-2474-y)
269 [2474-y](https://doi.org/10.1007/s00520-014-2474-y).
- 270 25 van Roij J, Brom L, Youssef-El Soud M, et al. Social consequences of advanced cancer in patients
271 and their informal caregivers: a qualitative study. *Support Care Cancer* 2019;27:1187–95.
272 doi:[10.1007/s00520-018-4437-1](https://doi.org/10.1007/s00520-018-4437-1).
- 273 26 Kaul S, Avila JC, Mehta HB, et al. Cost-related medication nonadherence among adolescent and
274 young adult cancer survivors. *Cancer* 2017;123:2726–34. doi:[10.1002/cncr.30648](https://doi.org/10.1002/cncr.30648).
- 275 27 Chung GC, Marottoli RA, Cooney LM, et al. Cost-related medication nonadherence among older
276 adults: findings from a nationally representative sample. *J Am Geriatr Soc* 2019;67:2463–73.
277 doi:[10.1111/jgs.16141](https://doi.org/10.1111/jgs.16141).
- 278 28 Jan S, Laba TL, Essue BM, et al. Action to address the household economic burden of non-
279 communicable diseases. *Lancet* 2018;391:2047–58. doi:[10.1016/S0140-6736\(18\)30323-4](https://doi.org/10.1016/S0140-6736(18)30323-4).
- 280 29 Lim JN, Potrata B, Simonella L, et al. Barriers to early presentation of self-discovered breast cancer
281 in Singapore and Malaysia: a qualitative multicentre study. *BMJ Open* 2015;5:e009863.
282 doi:[10.1136/bmjopen-2015-009863](https://doi.org/10.1136/bmjopen-2015-009863).
- 283 30 Ruddy K, Mayer E, Partridge A. Patient adherence and persistence with oral anticancer treatment.
284 *CA Cancer J Clin* 2009;59:56–66. doi:[10.3322/caac.20004](https://doi.org/10.3322/caac.20004).
- 285 31 Fenn KM, Evans SB, McCorkle R, et al. Impact of financial burden of cancer on survivors' quality
286 of life. *J Oncol Pract* 2014;10:332–8. doi:[10.1200/JOP.2013.001322](https://doi.org/10.1200/JOP.2013.001322).
- 287 32 Mongelli MN, Giri S, Peipert BJ, et al. Financial burden and quality of life among thyroid cancer
288 survivors. *Surgery* 2020;167:631–7. doi:[10.1016/j.surg.2019.11.014](https://doi.org/10.1016/j.surg.2019.11.014).
- 289 33 Jacob J, Palat G, Verghese N, et al. Health-related quality of life and its socio-economic and cultural
290 predictors among advanced cancer patients: evidence from the APPROACH cross-sectional survey in
291 Hyderabad-India. *BMC Palliat Care* 2019;18:94. doi:[10.1186/s12904-019-0465-y](https://doi.org/10.1186/s12904-019-0465-y).
- 292 34 Altice CK, Banegas MP, Tucker-Seeley RD, et al. Financial hardships experienced by cancer
293 survivors: a systematic review. *J Natl Cancer Inst* 2017;109. doi:[10.1093/jnci/djw205](https://doi.org/10.1093/jnci/djw205).
- 294 35 van Dongen SI, de Nooijer K, Cramm JM, et al. Self-management of patients with advanced cancer:
295 a systematic review of experiences and attitudes. *Palliat Med* 2020;34:160–78.
296 doi:[10.1177/0269216319883976](https://doi.org/10.1177/0269216319883976).

- 1
2
3
4 297 36 Cheng Q, Liu X, Li X, et al. Improving spiritual well-being among cancer patients: implications for
5 298 clinical care. *Support Care Cancer* 2019;27:3403–9. doi:[10.1007/s00520-019-4636-4](https://doi.org/10.1007/s00520-019-4636-4).
- 7 299 37 Wang CW, Chow AY, Chan CL. The effects of life review interventions on spiritual well-being,
8 300 psychological distress, and quality of life in patients with terminal or advanced cancer: a systematic
9 301 review and meta-analysis of randomized controlled trials. *Palliat Med* 2017;31:883–94.
10 302 doi:[10.1177/0269216317705101](https://doi.org/10.1177/0269216317705101).
- 12 303 38 Lyckholm LJ, Coyne PJ, Kreutzer KO, et al. Barriers to effective palliative care for low-income
13 304 patients in late stages of cancer: report of a study and strategies for defining and conquering the barriers.
14 305 *Nurs Clin North Am* 2010;45:399–409. doi:[10.1016/j.cnur.2010.03.007](https://doi.org/10.1016/j.cnur.2010.03.007).
- 16 306 39 Yeager KA, Sterk CE, Quest TE, et al. Managing One’s symptoms: a qualitative study of low-
17 307 income African Americans with advanced cancer. *Cancer Nurs* 2016;39:303–12.
18 308 doi:[10.1097/NCC.0000000000000284](https://doi.org/10.1097/NCC.0000000000000284).
- 20 309 40 Balboni T, Balboni M, Paulk ME, et al. Support of cancer patients’ spiritual needs and associations
21 310 with medical care costs at the end of life. *Cancer* 2011;117:5383–91. doi:[10.1002/cncr.26221](https://doi.org/10.1002/cncr.26221).
- 23 311 41 Fitch MI, Sharp L, Hanly P, et al. Experiencing financial toxicity associated with cancer in publicly
24 312 funded healthcare systems: a systematic review of qualitative studies. *J Cancer Surviv* 2021.
25 313 doi:[10.1007/s11764-021-01025-7](https://doi.org/10.1007/s11764-021-01025-7).
- 27 314 42 Lockwood C, Munn Z, Porritt K. Qualitative research synthesis: methodological guidance for
28 315 systematic reviewers utilizing meta-aggregation. *Int J Evid Based Healthc* 2015;13:179–87.
29 316 doi:[10.1097/XEB.0000000000000062](https://doi.org/10.1097/XEB.0000000000000062).
- 31 317 43 Aromataris E, Briggs MZJ. *Institute reviewer’s manual*. The Joanna Briggs Institute 2017.
- 33 318 44 Pearson A. Balancing the evidence: incorporating the synthesis of qualitative data into systematic
34 319 reviews. *JBIR* 2004;2:45–64. doi:[10.1111/j.1479-6988.2004.00008.x](https://doi.org/10.1111/j.1479-6988.2004.00008.x).
- 36 320 45 Munn Z, Porritt K, Lockwood C, et al. Establishing confidence in the output of qualitative research
37 321 synthesis: the ConQual approach. *BMC Med Res Methodol* 2014;14:108. doi:[10.1186/1471-2288-14-108](https://doi.org/10.1186/1471-2288-14-108).
- 39 322 46 Tong A, Flemming K, McInnes E, et al. Enhancing transparency in reporting the synthesis of
40 323 qualitative research: ENTREQ. *BMC Med Res Methodol* 2012;12:181. doi:[10.1186/1471-2288-12-181](https://doi.org/10.1186/1471-2288-12-181).
- 42 324
43 325
44 326

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

327 **Authors' contributions:** ZA and XM contributed to the conception and design of the study. ZA and XM
328 contributed equally. The introduction was written by ZA and XM. The methods, including literature
329 retrieval, data extraction and appraisal, risk offset assessment, and data synthesis, were drafted by HY
330 and LY. In addition, PF, LY, and HY assisted in clarifying differences to avoid errors. All authors
331 contributed to the final manuscript and agreed to its publication.

332 **Funding:** This work was supported by the Health Commission of Hubei Province Scientific Research
333 Project [grant number WJ2019M176].

334 **Competing interests:** None declared.

335 **Word count:** 1835 words

336 **Patient consent for publication:** Not required.

337 **Figure:** Figure 1. PRISMA flow diagram of the study process. PRISMA, Preferred Reporting Items for
338 Systematic Reviews and Meta-Analysis.

339 ORCID

340 Zifen An <https://orcid.org/0000-0002-1624-8153>

341 Xianmei Meng <https://orcid.org/0000-0003-0036-2733>

342 Pei Fang <https://orcid.org/0000-0003-1922-4955>

343 Huidan Yu <https://orcid.org/0000-0002-5353-3025>

344 Liping Yu <https://orcid.org/0000-0002-3202-3472>




Figure1 PRISMA-P flow diagram of the protocol process. PRISMA-P, Preferred reporting items for systematic review and meta-analysis protocols.

Reporting checklist for protocol of a systematic review and meta-analysis.

Based on the PRISMA-P guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the PRISMA-Preorting guidelines, and cite them as:

Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. *Syst Rev.* 2015;4(1):1.

		Reporting Item	Page Number
Title			
Identification	#1a	Identify the report as a protocol of a systematic review	1
Update	#1b	If the protocol is for an update of a previous systematic review, identify as such	n/a
Registration			
	#2	If registered, provide the name of the registry (such as PROSPERO) and registration number	2
Authors			
Contact	#3a	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author	1
Contribution	#3b	Describe contributions of protocol authors and identify the	13

guarantor of the review

Amendments

#4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	n/a
--------------------	---	-----

Support

Sources	#5a	Indicate sources of financial or other support for the review	13
Sponsor	#5b	Provide name for the review funder and / or sponsor	13
Role of sponsor or funder	#5c	Describe roles of funder(s), sponsor(s), and / or institution(s), if any, in developing the protocol	13

Introduction

Rationale	#6	Describe the rationale for the review in the context of what is already known	4,5
Objectives	#7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	6

Methods

Eligibility criteria	#8	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review	6
Information sources	#9	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage	6
Search strategy	#10	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated	6
Study records - data management	#11a	Describe the mechanism(s) that will be used to manage records and data throughout the review	7
Study records -	#11b	State the process that will be used for selecting studies (such	7

1	selection process		as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)	
2				
3				
4				
5	Study records -	#11c	Describe planned method of extracting data from reports	7
6	data collection		(such as piloting forms, done independently, in duplicate),	
7	process		any processes for obtaining and confirming data from	
8			investigators	
9				
10				
11				
12	Data items	#12	List and define all variables for which data will be sought	7
13			(such as PICO items, funding sources), any pre-planned data	
14			assumptions and simplifications	
15				
16				
17	Outcomes and	#13	List and define all outcomes for which data will be sought,	n/a
18	prioritization		including prioritization of main and additional outcomes, with	
19			rationale	
20				
21				
22				
23	Risk of bias in	#14	Describe anticipated methods for assessing risk of bias of	7
24	individual studies		individual studies, including whether this will be done at the	
25			outcome or study level, or both; state how this information will	
26			be used in data synthesis	
27				
28				
29	Data synthesis	#15a	Describe criteria under which study data will be quantitatively	n/a
30			synthesised	
31				
32				
33	Data synthesis	#15b	If data are appropriate for quantitative synthesis, describe	n/a
34			planned summary measures, methods of handling data and	
35			methods of combining data from studies, including any	
36			planned exploration of consistency (such as I ² , Kendall's τ)	
37				
38				
39				
40	Data synthesis	#15c	Describe any proposed additional analyses (such as	n/a
41			sensitivity or subgroup analyses, meta-regression)	
42				
43				
44	Data synthesis	#15d	If quantitative synthesis is not appropriate, describe the type	8
45			of summary planned	
46				
47				
48	Meta-bias(es)	#16	Specify any planned assessment of meta-bias(es) (such as	n/a
49			publication bias across studies, selective reporting within	
50			studies)	
51				
52				
53	Confidence in	#17	Describe how the strength of the body of evidence will be	8
54	cumulative		assessed (such as GRADE)	
55	evidence			
56				
57				
58	Notes:			

- 1 •1b: n/a. This is a protocol for a new systematic review.
2
3 •4: n/a. This protocol will be published for the first time.
4
5 •15a, 15b, 15c,16: n/a. This is an integration of qualitative evidence, and the criteria for quantitative
6 synthesis do not apply.
7
8
9
10

11 The PRISMA-P elaboration and explanation paper is distributed under the terms of the Creative
12 Commons Attribution License CC-BY. This checklist was completed on 24. November 2021 using
13 <https://www.goodreports.org/>, a tool made by the [EQUATOR Network](#) in collaboration with
14 [Penelope.ai](#)
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Supplement material 2: Search strategy

Example search strategy for PubMed

#1 "Neoplasms"[Mesh] OR "tumor"[Title/Abstract] OR "cancer" [Title/Abstract] OR "carcinoma"[Title/Abstract]

#2 "terminal"[Title/Abstract] OR "advanced"[Title/Abstract] OR "late stage"[Title/Abstract] OR "end stage"[Title/Abstract] OR "end of life"[Title/Abstract] OR "metastatic"[Title/Abstract]

#3 "Social Class"[Mesh] OR "socioeconomic status"[Title/Abstract] OR "socioeconomic"[Title/Abstract] OR "social environment"[Title/Abstract] OR "social support"[Title/Abstract] OR "economic"[Title/Abstract] OR "poor"[Title/Abstract] OR "income"[Title/Abstract] OR "low income"[Title/Abstract] OR "poverty"[Title/Abstract] OR "unemployment"[Title/Abstract] OR "employment"[Title/Abstract]

#4 "Qualitative Research"[Mesh] OR "Focus Groups"[Mesh] OR "Interview as topic"[Mesh] OR "Hermeneutics"[Mesh] OR "Grounded Theory"[Mesh] OR "Personal Narrative"[Mesh] OR "Feminism"[Mesh] OR "Life Change Events"[Mesh] OR "Anthropology, Cultural"[Mesh] OR "qualitative"[Title/Abstract] OR "group focus"[Title/Abstract] OR "groups focus"[Title/Abstract] OR "grounded theory"[Title/Abstract] OR "grounded analysis"[Title/Abstract] OR "grounded analyses"[Title/Abstract] OR (stud*[Title/Abstract] AND "grounded"[Title/Abstract]) OR "narrative analysis"[Title/Abstract] OR "feminist ethics"[Title/Abstract] OR "ethics, feminist "[Title/Abstract] OR (experience*[Title/Abstract] AND "life"[Title/Abstract]) OR "analysis, event history"[Title/Abstract] OR "event history analysis"[Title/Abstract] OR experience*[Title/Abstract] OR "Cultural Anthropology"[Title/Abstract] OR ethnograph*[Title/Abstract]

#5 #1 AND #2 AND #3 AND #4

1
2
3
4 **Supplemental material 3:**
5

6 **JBI Critical Assessment Checklist**
7

8

Methodology	Yes	No	Unclear	Not applicable
1. Is there congruity between the stated philosophical perspective and the research methodology?				
2. Is there congruity between the research methodology and the research question or objectives?				
3. Is there congruity between the research methodology and the methods used to collect data?				
4. Is there congruity between the research methodology and the representation and analysis of data?				
5. Is there congruity between the research methodology and the interpretation of results?				
6. Is there a statement locating the researcher culturally or theoretically?				
7. Is the influence of the researcher on the research, and vice-versa, addressed?				
8. Are participant, and their voices, adequately represented?				
9. Is the research ethical according to current criteria or, for recent studies, and is there evidence of ethical approval by an appropriate body?				
10. Do the conclusions drawn in the research report flow from the analysis or interpretation, of the data?				
Overall appraisal:	Include			Exclude
Seek further info				
Comments (Including reason for exclusion):				

9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Supplemental material 4:

JBI Qualitative Assessment and Review Instrument Data Extraction

Study (Name and authors)	Methodology	Methods	Phenomenon of interest	Setting	Geographical location	Cultural	Participants	Data analysis	Author conclusion	Comments

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Supplemental material 5:

JBI ConQual summary of findings

Systematic review title: Living experiences of advanced cancer patients with low socioeconomic status: Protocol for a systematic review of qualitative evidence.

Population: Patients with advanced cancer, without limitations on the country or type of cancer.

Phenomena of interest: The life experiences of patients with advanced cancer, including disease distress, barriers, and strategies in detail.

Context: The life experiences of advanced cancer patients with low SES.

Synthesised finding	Type of research	Dependability	Credibility	ConQual score

Supplemental material 6:**Enhancing transparency in reporting the synthesis of qualitative research: the ENTREQ statement**

No	Item	Guide and description
1	Aim	State the research question the synthesis addresses.
2	Synthesis methodology	Identify the synthesis methodology or theoretical framework which underpins the synthesis and describe the rationale for choice of methodology.
3	Approach to searching	Indicate whether the search was pre-planned or iterative.
4	Inclusion criteria	Specify the inclusion/exclusion criteria.
5	Data sources	Describe the information sources used and when the searches conducted; provide the rationale for using the data sources.
6	Electronic Search strategy	Describe the literature search.
7	Study screening methods	Describe the process of study screening and sifting.
8	Study characteristics	Present the characteristics of the included studies.
9	Study selection results	Identify the number of studies screened and provide reasons for study exclusion.
10	Rationale for appraisal	Describe the rationale and approach used to appraise the included studies or selected findings.
11	Appraisal items	State the tools, frameworks, and criteria used to appraise the studies or selected findings.
12	Appraisal process	Indicate whether the appraisal was conducted independently by more than one reviewer and if consensus was required.
13	Appraisal results	Present results of the quality assessment and indicate which articles, if any, were weighted/excluded based on the assessment and give the rationale.
14	Data extraction	Indicate which sections of the primary studies were analysed and how were the data extracted from the primary studies?
15	Software	State the computer software used, if any.
16	Number of reviewers	Identify who was involved in coding and analysis.
17	Coding	Describe the process for coding of data.
18	Study comparison	Describe how were comparisons made within and across studies.
19	Derivation of themes	Explain whether the process of deriving the themes or constructs was inductive or deductive.

1		
2		
3		
4		
5		
6		
7		
8		
9		
10		
11		
12		
13		
14		
15		
16		
17		
18		
19		
20		
21		
22		
23		
24		
25		
26		
27		
28		
29		
30		
31		
32		
33		
34		
35		
36		
37		
38		
39		
40		
41		
42		
43		
44		
45		
46		
47		
48		
49		
50		
51		
52		
53		
54		
55		
56		
57		
58		
59		
60		
20	Quotations	Provide quotations from the primary studies to illustrate themes/constructs and identify whether the quotations were participant quotations of the author's interpretation.
21	Synthesis output	Present rich, compelling, and useful results that go beyond a summary of the primary studies.

For peer review only